Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

NCT03608020 is registered in ClinicalTrials.gov with BioMimetix JV, LLC as lead sponsor.

NCT NCT03608020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03608020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Lead sponsor
BioMimetix JV, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
October 4, 2018
Completion date
April 15, 2024
Enrollment
35 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple brain metastases